Introduction {#s1}
============

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder of women of reproductive age. PCOS can present as infertility, oligomenorrhoea, hirsuitism, acne, hyperandrogenaemia and/or obesity and have metabolic consequences such as an increased risk of hypertension, insulin resistance and type 2 diabetes in later life ([@DEU268C15]; [@DEU268C51]; [@DEU268C42]). Women with PCOS are also known to have an increased risk of obstetric complications including pre-eclampsia (PE), gestational diabetes and preterm birth ([@DEU268C36]; [@DEU268C8]; [@DEU268C1]; [@DEU268C29]; [@DEU268C19]).

A systematic review performed recently showed that the pregnant women who are known to have PCOS were four times more likely to develop PE when compared with controls ([@DEU268C29]). Although the association between PCOS and PE has been documented, the underlying pathophysiological mechanisms involved are not completely understood; however, it is possible that the raised androgen levels, hyperinsulinaemia and subsequent diabetic and hypertensive susceptibilities in PCOS may act as co-factors ([@DEU268C48]). Among the various implicating factors, defective placental vasculature appears to be central to the disease ([@DEU268C14]).

Currently, there is insufficient evidence to establish causation and to establish screening for patients for these complications, solely based on PCOS diagnosis. There is however a need for research studies into the molecular mechanisms underpinning the link between PCOS and PE. This could facilitate screening in women with PCOS for PE, which could minimize the occurrence of maternal and fetal morbiditiy/mortality associated with PE in pregnant women with PCOS. Proteomic biomarker discovery programmes may address this need.

PE is pregnancy-induced hypertension in association with proteinuria (\>0.3 g in 24 h) with or without oedema ([@DEU268C43]). Virtually, any organ system may be affected. The incidence of severe PE is ∼5 in 1000 maternities and is a major cause of poor pregnancy outcomes, including severe obstetric morbidity and maternal and fetal mortality ([@DEU268C43]). PE is associated with fetal growth restriction, low birthweight, preterm delivery and respiratory distress syndrome ([@DEU268C43]). Pregnant women who are at high risk of developing PE can be identified in the early antenatal period from a comprehensive history enquiring about risk factors, including previous history or family history of PE, age and BMI as well as co-morbidities such as hypertension, renal disease and diabetes ([@DEU268C14]). PE is still the second most common cause of maternal mortality as reported by the confidential enquiry into Maternal and Child Health for the triennium of 2006--2008 ([@DEU268C12]). The exact pathophysiological mechanism of PE is still unknown.

Proteomics is an emerging discipline which involves the global analysis of protein expression changes ([@DEU268C2]). There is a common consensus that the information obtained from the protein component of the cell or tissue complements the genomic data. Alterations in protein expression depict biological processes as proteins are the vital elements that control cell function. Proteomic methods are appropriate to detect post-translational alterations. In a literature review of MEDLINE (1966--December 2013), EMBASE (1980--December 2013), ISI web of knowledge (v4.2) and Cochrane (1993--December 2013) databases combining the terms: 'proteomics\', 'proteomic', 'preeclampsia', and 'PCOS\' or 'polycystic ovary syndrome', no studies were isolated, where proteomic biomarkers for PE had been specifically investigated in women with PCOS. However, several studies were identified where proteomic techniques had been used in the study of pregnant women with PE and in women with PCOS as separate entities.

The present study aimed at systematically reviewing the research undertaken using proteomic technologies for the detection of proteomic biomarkers in PE and consider whether any of these biomarkers could be used as candidate biomarkers for identifying the women with PCOS who are at risk of developing PE in pregnancy. This was achieved by performing a comparison of PE biomarkers against previously a published database of all proteomic biomarkers identified so far in women with PCOS ([@DEU268C3]). Any biomarkers found to be common to both conditions could be investigated in future studies to understand the mechanisms that link PE with PCOS.

Methods {#s2}
=======

This study did not involve patient contact; hence, Institutional Review Board (IRB) approval was not mandatory.

Studies eligible for review {#s2a}
---------------------------

MEDLINE (1966--December 2013), EMBASE (1980--December 2013), Cochrane (1993--December 2013) and ISI web of knowledge (v4.2) databases were searched using the terms 'proteomics\', 'proteomic', 'pre-eclampsia', 'pre-eclamptic toxemia', 'proteomic biomarker', and 'polycystic ovary syndrome' without any restrictions. Animal studies were not included in the review.

Data abstraction {#s2b}
----------------

The original PDFs of studies were acquired through online links to the files obtained from the search results. The references from the studies were manually searched to identify any other relevant studies. The search criterion ended in December 2013. The searches were independently conducted by two of the authors (G.H.K. and N.D.).

Main characteristics of the PE studies {#s2c}
--------------------------------------

The selected studies were assessed and a record was made of the specific study characteristics including type of study, design, number of participants (*n*), type of proteomic technique used and the exact nature of the sample analysed in each study (whether serum, urine etc.). A list of proteins was created, that were identified to have been expressed differently in women with PE versus controls (normal pregnancy). These parameters are presented in Table [I](#DEU268TB1){ref-type="table"}. To improve accuracy, the studies were screened independently by two of the co-authors (G.H.K., N.D.). Table IThe main characteristics of each study and the proteins differentially expressed in patients with PE compared with normal individuals.StudyPopulationSelection criteriaProteins identifiedChange versus control (↑/↓)Sample siteTechnique used*n*Mean age ± SD\
age rangeInclusionExclusion[@DEU268C17]Control, *n* = 633.2 ± 2.6Normotensive pregnant patientsNAFN1 proteinDecreasedPlacentaLC-ESI-MS/MSPE, *n* = 438.8 ± 2.3Systolic blood pressure level ≥ 160 mmHg or a diastolic blood pressure level ≥ 110 mmHg on two occasions and proteinuria ≥3+ on a urine stick or ≥5 g in a 24-h urine specimen (ACOG practice, 2002)α-Actinin-4DecreasedActinIncreasedTransgelin-2DecreasedPregnancy-specific β-1-glycoprotein 3IncreasedChoriogonadotrophin subunit βIncreasedPregnancy-specific β-1-glycoprotein 2IncreasedProtein Si00-A11DecreasedPregnancy-specific β-1-glycoprotein 4IncreasedPhosphatidylethanolamine-binding protein 1Decreasedβ-2-microglobulinDecreasedCoagulation factor XIII A chainDecreasedFollistatin-related protein 1DecreasedMalate dehydrogenaseIncreasedAnnexin A2DecreasedThioredoxin domain-containing protein 4DecreasedSerotransferrinDecreasedC9orf88 variant protein (Fragment)IncreasedCystatin-MDecreasedPolypyrimidine tract-binding protein 1Decreased40S ribosomal protein S5IncreasedCalnexinDecreasedSerine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A α isoformIncreased[@DEU268C9]38 = PE 21 = controlNASevere PE (sPE)NA21-aa C-terminus fragment of SERPINA-1IncreasedUrine+ PlacentaSELDI-TOF-MS206 (cross-sectional cohort)\
19 (longitudnal cohort)Low risk of PE (*n* = 4)\
High risk of PE (*n* = 15)24-aa N-terminus fragment of SERPINA-1Increased[@DEU268C38]PE, *n* = 1832.5 ± 4.7Blood pressure ≥140/90 after 20 weeks and proteinuriaMultiple pregnancyProapolipoprotein A-IIncreasedAmniotic fluidSELDI-TOF-MSChronic hypertension, *n* = 733.0 ± 4.5Blood pressure ≥140/90 before pregnancy or after 20 weeksEvidence of intrauterine infectionSBBI42IncreasedWestern blotControl, *n* = 1631.6 ± 3.0No evidence of high blood pressure or proteinuria[@DEU268C26]Control, *n* = 6NANo evidence of high blood pressure or proteinuriaSmokers Diabetes IUGR Medication other than antihypertensivesα-2-HS-glycoproteinIncreasedPlacentaLC-MS/MSPE, *n* = 6Blood pressure ≥140/90 after 20 weeks and proteinuriaGlutathione *S*-transferaseDecreasedWestern blotPeroxiredoxin 6DecreasedAldose reductaseDecreasedHeat shock protein 60Decreasedβ-TubulinDecreasedHeat shock protein 70DecreasedProteasome, α subunitDecreasedEzrinDecreasedProtein disulphide isomerizeDecreasedPhosphoglycerate mutase 1DecreasedTriosephosphate isomeraseDecreased[@DEU268C21]Normal, *n* = 524.1 ± 3No evidence of high blood pressure or proteinuriaMultigravidaHeat shock protein gp96 precursorDecreasedPlacentaMALDI TOF/TOFsPE, *n* = 524.3 ± 2.4Blood pressure, 160 mmHg or higher systolic or 110 mmHg or higher diastolic on two occasions at least 6 h apart, and new onset of proteinuria, 500 mg or more of protein in a 24 h urine collection or 3+ or greater on urine dipstick testing of two random urine samples collected at least 4 h apartVaginal birthChloride intracellular channel 3IncreasedChain A of enoyl-co-enzyme A hydrataseDecreasedChain A, crystal structure of human Apolipoprotein A-IDecreasedProtein disulphide isomeraseIncreasedCu/Zn-superoxide dismutaseIncreasedActin, γ 1 pro-peptideDecreasedPeroxiredoxin 3, isoform CRA-aDecreasedHSPA8 (Hsc 70)DecreasedPeroxiredoxin 2 isoform aDecreasedChain A, TransthyretinDecreased[@DEU268C6]Normal, *n* = 5729.7Plasma obtained at 20 ± 1 week gestation from the SCOPE biobank. No evidence of high blood pressure or proteinuriaNAFibronectin 1 isoform 3 preproproteinIncreasedSerumLC-MS/MSPE (appropriate growth for gestation), *n* = 2730Blood pressure ≥140/90 after 20 weeks on two occasions 4 h apart and combined with either proteinuria or multi-organ complicationFibrinogen, β chain preproproteinIncreasedWestern BlotPE (small for gestation age), *n* = 1230.3Customized birthweight less than tenth centile for gestational ageClusterin isoform 1IncreasedTTRIncreasedApolipoprotein A-I precursorIncreasedHemopexinIncreasedTransferrinIncreased[@DEU268C50]Normal pregnant women *n* = 8030.3 ± 4.3No evidence of high blood pressure or proteinuriaNAFibrinogen γ chainIncreasedSerum2-Dimensional electrophoresis MALDI-TOF-MS Western BlotPE *n* = 8030.6 ± 5.3Diagnosis of PE was based on the criteria of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancyα-1-antichymotrypsinIncreased[@DEU268C5]Normal pregnant *n* = 23NANo evidence of high blood pressure or proteinuriaNAClusterinIncreasedPlasmaMALDI TOF/TOFPE *n* = 23PE was diagnosed using standard definitions from the International Society for the Study of Hypertension in PregnancyApolipoprotein BIncreasedInter-α inhibitor H1IncreasedInter-α inhibitor H2IncreasedInter-α inhibitor H3IncreasedComplement C6IncreasedComplement C7IncreasedPAPP-AIncreasedVitamin K-dependent protein ZIncreasedComplement C1sIncreasedSex hormone-binding globulinIncreasedClusterinIncreasedCoagulation factor XIncreasedCoagulation factor VIncreasedInsulin-like growth factor binding protein complex acid labile chain precursor (ALS)IncreasedPregnancy-specific B-1 glycoprotein 11IncreasedPregnancy-specific B-1 glycoprotein 1IncreasedVitamin D binding protein^a^IncreasedSerum amyloid P-componentIncreasedComplement C2IncreasedPregnancy-specific glycoprotein 9IncreasedParaoxonase 1IncreasedPeroxiredoxin-2IncreasedCarboxypeptidase N catalytic chainDecreasedVitamin D binding proteinDecreasedα-2-macroglobulinDecreasedVitronectin precursorDecreasedAfamin precursor (α-albumin)DecreasedFibronectin 1DecreasedTrypsin-1DecreasedExtracellular matrix protein 1DecreasedComplement C1qDecreasedPlasma protease C1 inhibitorDecreasedFetuin-ADecreasedZinc finger proteinDecreasedComplement C 4BDecreased[@DEU268C34]Normal pregnant *n* = 528.2 ± 1.8No evidence of high blood pressure or proteinuriaNASerpin peptidase inhibitor, clade A, member 1IncreasedPlasmaLC-MS/MSsPE *n* = 530.3 ± 2.4Severe PE was defined as increased blood pressure (≥160 mmHg systolic or ≥110 mmHg diastolic on ≥2 occasions at least 6 h apart) that occurred after 20 weeks of gestation in women with preciously normal blood pressure, accompanied with proteinuria (≥5 g/24 h) or proteinuria of 2+ or more by dipstick measurementα-2-HS-glycoproteinIncreasedAMBP proteinIncreasedApolipoprotein EIncreasedApolipoprotein HIncreasedCeruloplasminIncreasedChorionic somatomammotropin hormoneIncreasedClusterinIncreasedCoagulation factor XIncreasedComplement C1q subcomponent subunit AIncreasedComplement C1q subcomponent subunit CIncreasedComplement component C8 β chainIncreasedComplement component C9IncreasedComplement factor HIncreasedComplement factor H-related 1IncreasedComplement factor properdinIncreasedFibrinogen α chainIncreasedFibrinogen β chainIncreasedFibrinogen γ chainIncreasedFibronectinIncreasedFibulin-1IncreasedGalectin-3-binding proteinIncreasedHyaluronan-binding protein 2IncreasedKininogen-1IncreasedLysozyme CIncreasedSerpin peptidase inhibitor, clade F, member 1IncreasedPlasminogenIncreasedPregnancy-specific β-1-glycoprotein 3IncreasedPregnancy-specific β-1-glycoprotein 4IncreasedVitamin D-binding proteinIncreasedVitronectinIncreasedα-2-macroglobulinIncreasedAngiogeninIncreasedSerpin peptidase inhibitor, clade C, member 1IncreasedApolipoprotein A-IIDecreasedApolipoprotein B-100DecreasedApolipoprotein-L1DecreasedC4b-binding protein α chainDecreasedComplement factor H-related protein 1DecreasedGlutathione peroxidase 3DecreasedHaemoglobin subunit αDecreasedHaemoglobin subunit ςDecreasedLeucine-rich repeat-containing protein 6DecreasedMannan-binding lectin serine protease 2DecreasedPlasma retinol-binding protein 4DecreasedPlatelet factor 4DecreasedPregnancy zone proteinDecreasedSerum amyloid A2 proteinDecreasedSerum amyloid A-4 proteinDecreasedSerum amyloid P-componentDecreasedTransthyretinDecreasedTotal = 267Working Group Criteria on high blood pressure in pregnancyNAMatrix metalloprtoteinase-9DecreasedDecreased2D-LC-MS/MS[@DEU268C40]Clinical Cohort:118 Mild PE *n* = 3028.3FibronectinIncreasedSevere PE *n* = 3027.8Pappalysin-2IncreasedNormotensive *n* = 5828.8Choriogonadotrophin-βIncreasedPreclinical cohort: *n* = 149 Mild PE *n* = 30Apolipoprotein C IIIIncreasedsPE *n* = 40Cystatin CIncreasedNormotensive *n* = 79sFlt-1IncreasedsPE *n* = 8EndoglinIncreasedPre clinical cohortComplement factor DIncreasedVascular cell adhesion protein 1Increasedβ-2-microglobulinIncreasedCystatin-CIncreasedPappalysinDecreasedControl *n* = 8NANormotensive pregnant womenNAHeat shock 27 kDa protein 1IncreasedPlacentaLC-MS/MS[@DEU268C25]PE *n* = 8Hypertension was defined as a blood pressure \>140 mm/Hg (systolic) or \>90 mm/Hg (diastolic) on at least two occasions and at least 4--6 h apart after the 20th week of gestation in women known to be normotensive beforehand78 kDa glucose-regulated protein precursorIncreasedTitinDecreasedProhibitinIncreasedCalnexinDecreasedAnnexin A1IncreasedNADH-ubiquinone oxidoreductase 24 kDaIncreasedChloride intracellular channel protein 3IncreasedSmooth muscle and non-muscle myosin alkali light chain isoform 1IncreasedActin α 1 skeletal muscle proteinIncreasedKeratin 10IncreasedCentrosome prIncreased[@DEU268C49]Controls *n* = 535 yearsNormotensive and women diagnosed with PEWomen with pre-gestational diseases and pregnancy complicationsTransthyretinIncreasedAmniotic fluidMALDI-TOF-MSPE *n* = 535years[@DEU268C37]*Taining set* Controls *n* = 20026.8 (6.4)Normotensive patientsNAIGFALSIncreasedPlasmaMS-MALDIPE *n* = 10026.6 (6.0)PE = hypertension associated with proteinuria. Hypertension was defined as a blood pressure \>140 mm/Hg (systolic) or \>90 mm/Hg (diastolic) on at least two occasions and at least 4--6 h apart after the 20th week of gestation in women known to be normotensive beforehandMCAMDecreased*Validation set* Controls *n* = 25028.9 (5.3)Proteinuria = renal excretion of at least 300 mg of proteins in a 24 h urine samplePE *n* = 5029.7 (5.5)[@DEU268C11]Control *n* = 3035.1No evidence or previous history of PEPatients with other systemic diseasesApolipoprotein 1IncreasedPlacentaMALDI --TOF MS/2-DPAGE/Western blotPE *n* = 3035.1PE was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or both, on 2 occasions 4 h apart after 20 weeks\' gestation but before the onset of labour, or post-partum, with either proteinuria (24-h urinary protein ≥300 mg or spot urine protein:creatinine ratio ≥30 mg/mmol creatinine or urine dipstick protein ++) or any multisystem complication of PETropomyosin -3Decreased[@DEU268C30]Control *n* = 630.7 (2.9)NormotensiveNAFibrinogen Fragment DIncreasedPlasmaMALDI-TOF/TOF iTRAQPE *n* = 631.7 (1.8)PE = blood pressure above 140/90 mmHg and proteinuria above 0.3 g/l or rise in blood pressure above 20 mmHg from the first trimester of pregnancyClusterin isoform 2IncreasedApolipoprotein A-IIncreasedFibronectinIncreasedAngiotensinogenIncreasedGalectin 3 bindingIncreasedPlasminogenIncreasedTransferrinIncreasedC4 β bindingIncreasedHaemopexinIncreased[@DEU268C7]Control *n* = 6Healthy pregnancy outcomeNAVitronectin 75 kDaIncreasedPE *n* = 6PE was defined as systolic blood pressure (BP) ≥140 mm Hg and/or diastolic BP ≥ 90 mm Hg on 2 or more occasions after 20 weeks' gestation but prior to the onset of labour, or post-partum systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mm Hg post-partum on at least 2 occasions 4 h apart, combined with either proteinuria (spot protein to creatinine ratio ≥30 mg/mmol, or 24-h urinary protein ≥0.3 g/24 h, or dipstick proteinuria ≥2+) or any multi-organ complicationVitronectin 65 kDaDecreasedPlasmaDIGE Western blot LC-MS/MSa-1-antichymotrypsin (SERPINA3)DecreasedKininogen-1Decreased[^1][^2]

Methodological quality assessment {#s2d}
---------------------------------

The QUADOMICS tool, which is an adaptation of QUADAS (a quality assessment tool for use in systematic reviews of the diagnostic accuracy studies) takes into account the particular challenges encountered using 'omics\' based techniques ([@DEU268C39]) and is recommended in studies using this methodology. The tool was applied to determine the methodological quality of the studies included in this systematic review (Table [II](#DEU268TB2){ref-type="table"}). The studies that achieved the score of 12/16 were classified as high quality (HQ), whereas those which scored 11/16 or less were classified as low quality (LQ). The methodological quality assessment was also performed independently by two of the co-authors (G.H.K. and N.D.). Table IIMethodological Quality Assessment using the QUADOMICS Tool.Quality criteria[@DEU268C17][@DEU268C9])[@DEU268C38])[@DEU268C26])[@DEU268C21])[@DEU268C6][@DEU268C50])[@DEU268C5])[@DEU268C34])1NYYNNNNNN2NYYNNYYYN3YYYYYYYYY4YYYNNYYNN5YYYYYYYYY6YYYYYYN/AYY7YYYYYYYYY8YNYYYYYYY9YNYYYYYYY10YYYYYYYYY11YYYYYYYNY12N/AYNNNNNNN13YYYYYYYYY14YYYYNYYYY15YYNN/ANYNNY16YYNNNNYNNTotal13141310913121011**Quality criteria[@DEU268C40][@DEU268C25][@DEU268C49][@DEU268C37][@DEU268C11][@DEU268C30][@DEU268C7]**1NNYYYNN2YNNYNYY3NNYYYYY4YNYYYYY5YYYYYYY6N/AYN/ANYYY7YYYYYYY8YYYYYYY9YYYYYYY10YYYYYYY11NYYYYNY12NNNYNNN13YYYYYYN14YNYYYYY15NN/AYNYYY16NNN/AYYYYTotal981214141313[^3]

The PCOS proteomics biomarkers database {#s2e}
---------------------------------------

The PCOS proteomic biomarkers data has been previously published and validated ([@DEU268C3]). A further literature search was however performed on MEDLINE (1966--December 2013), EMBASE (1980--December 2013) and the ISI web of knowledge (v4.2) databases using the following search terms 'polycystic ovary syndrome' and 'proteomic', 'proteomics', or 'proteomics biomarker' without any limits/restrictions. All relevant studies published since the database was last updated in February 2011 were reviewed. One relevant study has since been published, but the updated PCOS database already contained the listed biomarkers found in the paper.

Searching for PE biomarkers in the PCOS biomarker database {#s2f}
----------------------------------------------------------

A comparison was established between proteomic biomarkers for PE and the updated database of proteomic biomarkers for PCOS. Where overlaps were present, the name of the protein, the original tissue in women with PCOS and PE (where these biomarkers had been identified) and the protein function was recorded.

Results {#s3}
=======

Proteomic studies of PE {#s3a}
-----------------------

The selection process of the primary studies where proteomic methodologies were used for the identification of biomarkers of PE is shown in Fig. [1](#DEU268F1){ref-type="fig"}. The search generated 58 articles. Review articles, studies that did not use proteomic techniques or studies that did not compare PE with a normotensive (control) group were excluded. Moreover, studies involving animals only, studies presenting protein *m/z* values only rather than protein identifications, or those studies that compared different proteomic approaches were further excluded, leaving 16 primary studies eligible for this review ([@DEU268C50]; [@DEU268C49]; [@DEU268C9]; [@DEU268C25]; [@DEU268C38]; [@DEU268C5]; [@DEU268C6],[@DEU268C7]; [@DEU268C11]; [@DEU268C21]; [@DEU268C40]; [@DEU268C26]; [@DEU268C34]; [@DEU268C17]; [@DEU268C30]; [@DEU268C37]). Figure 1Flowchart showing selection of studies included in the systematic review.

There were a total of 1423 patients and controls in all of the selected studies and 192 different proteomic biomarkers for PE were identified. Six studies investigated placental tissue ([@DEU268C9]; [@DEU268C25]; [@DEU268C38]; [@DEU268C11]; [@DEU268C21]; [@DEU268C26]; [@DEU268C17]), one of which also assessed urine ([@DEU268C9]). Two studies used amniotic fluid ([@DEU268C49]; [@DEU268C38]), five used plasma ([@DEU268C5]; [@DEU268C7]; [@DEU268C34]; [@DEU268C30]; [@DEU268C37]) and finally, three used serum samples ([@DEU268C50]; [@DEU268C6]; [@DEU268C40]). These are summarized in Table [I](#DEU268TB1){ref-type="table"}.

Various proteomic techniques that were used in the 16 studies included SELDI-TOF (Surface-Enhanced Laser Desorption Ionization Time-Of-Flight), Mass Spectrometry and MALDI-TOF (Matrix-Assisted Laser Desorption Time-Of-Flight), with Mass Spectrometry and LC-MS/MS (Liquid Chromatography--Tandem Mass Spectrometry) being the most common (Table [I](#DEU268TB1){ref-type="table"}).

Assessing the quality of the relevant studies {#s3b}
---------------------------------------------

Out of the 16 studies, 10 were HQ, fulfilling 12 or more of the 16 QUADOMICS criteria ([@DEU268C50]; [@DEU268C49]; [@DEU268C9]; [@DEU268C38]; [@DEU268C6],[@DEU268C7]; [@DEU268C11]; [@DEU268C17]; [@DEU268C30]; [@DEU268C37]). The remaining six studies were LQ, achieving \>12 out of the 16 quality criteria ([@DEU268C25]; [@DEU268C5]; [@DEU268C21]; [@DEU268C40]; [@DEU268C26]; [@DEU268C34]) (Table [II](#DEU268TB2){ref-type="table"}).

Cross-referencing proteomic biomarkers identified in primary studies of PE with database of proteomic biomarkers for PCOS {#s3c}
-------------------------------------------------------------------------------------------------------------------------

The 192 proteomic biomarkers for PE were cross-referenced with the PCOS database to determine if any were also differentially expressed in PCOS. Five biomarkers were found to be differentially expressed in women with PE and with PCOS compared with controls. Transferrin, fibrinogen α, β and γ chain variants and kininogen-1 were increased and annexin 2 and peroxiredoxin 2 were decreased both in women with PCOS and women with PE. For PE, these biomarkers were found in serum, plasma and placenta, respectively, whereas in PCOS, the biomarkers identified were in serum, follicular fluid, ovarian and omental biopsy, respectively.

Overlaps of the proteomic biomarkers amongst the 16 studies included in this review were also identified and tabulated (Table [III](#DEU268TB3){ref-type="table"}). Table IIIOverlaps of the proteomic biomarkers amongst the studies included in this review.![](deu26801a.jpg)

Discussion {#s4}
==========

This is the first study that has identified a panel of five proteomic biomarkers which were similarly differentially expressed in women with PE and in women with PCOS. These are transferrin, fibrinogen α, β and γ chain variants, kininogen-1, annexin 2 and peroxiredoxin 2. These findings are of interest but they will need to be validated, and there is a need for future studies that should explore how these proteins interrelate. We have also examined the interactomes of the potential biomarkers using STRING (an online functional protein interaction network; <http://string-db.org/>). No evidence for functional interactions between the potential biomarkers (with the exception of the closely related fibrinogen α, β and γ proteins which do interact with each other) was found, although STRING did highlight the co-expression of fibrinogen β and kininogen-1. Thus, at present we are unable to present a pathway that rationalizes how changes in the different candidate biomarkers may relate to one another.

The five proteomic biomarkers identified might clarify the link between PCOS and PE. There is a constant and evolving theme from studies applying proteomic approaches in PCOS about the possible role of immune regulation/inflammation and antioxidants in the pathogenesis of the condition. Similarly, these two pathways have also been implicated in the pathogenesis of PE ([@DEU268C46]; [@DEU268C45]; [@DEU268C41]; [@DEU268C53]).

Annexin A2 was down-regulated both in patients with PE and PCOS, although in PCOS, it was found in ovarian biopsies and in PE. it was in placental biopsies. It is known that Annexin A2 is the key physiological receptor for plasminogen on the extracellular surface of endothelial cells ([@DEU268C22]). It causes fibrinolysis by accelerating tissue plasminogen activator ([@DEU268C27]) at the endothelial level, via insulin-stimulated plasma membrane translocation of the glucose transporter GLUT-4 ([@DEU268C32]; [@DEU268C24]). The down-regulation observed in PE tilts the coagulation/fibrinolysis balance towards enhanced coagulation and thrombosis ([@DEU268C22]; [@DEU268C35]). We thus postulate that since Annexin A2 is down-regulated both in women with PCOS and PE, it could be a strong candidate for a potential biomarker for the detection of PE in women with PCOS.

Annexin A2 and fibrinogen α, β and γ chains are central in regulating fibrinolysis and thrombosis and their altered expression might represent changes in permeability of the peripheral vessels and vasculature of the various tissues, including ovaries, causing fibrinolysis and abnormal fibrogenesis and thrombosis in PCOS ([@DEU268C22]). We speculate that the impaired expression of these proteins may account for the early pregnancy complications such as miscarriage and could impinge upon the cardiovascular system in PCOS patients due to hypofibrinolysis and thrombophilia ([@DEU268C22]).

Transferrin was found to be up-regulated in sera of women with PE and PCOS. It is an important β-globulin responsible for transporting iron to various tissues and promoting cell growth and development ([@DEU268C20]). Transferrin also plays a vital role in pregnancy where it is expressed significantly in the villous syncytiotrophoblasts in women with PE compared with those with normal pregnancies. The cause for this substantial expression in the placentae of pregnancies complicated by either gestational diabetes or PE could be the developing or existing fetal stress ([@DEU268C31]). Transferrin in high concentrations can inhibit FSH to interact with its receptors on the granulosa cells and this can affect the maturation of oocytes by decreasing the levels of cAMP ([@DEU268C28]). Transferrin is also known to be a stress/acute phase response molecule. Its upsurge in both women with PCOS and PE could be explained on the basis of the inflammatory constituent of the two conditions.

Kininogen-1 was found to be up-regulated both in women with PE and PCOS in plasma and omental biopsy, respectively. Kininogens play an important role in blood coagulation by helping to position optimally pre-kallikrein and factor XI next to factor XII and inhibiting the thrombin- and plasmin-induced aggregation of thrombocytes ([@DEU268C52]). Moreover, they are a mediator of inflammation and cause increases in vascular permeability, stimulation of nociceptors, and release of other mediators of inflammation ([@DEU268C52]). These mechanisms have been implicated in the pathogenesis of both PE and PCOS ([@DEU268C22]; [@DEU268C46]; [@DEU268C45]; [@DEU268C41]; [@DEU268C53]; [@DEU268C13]).

Peroxiredoxin 2 was found to be down-regulated in both PE and PCOS in placental and omental biopsy, respectively ([@DEU268C20]). In view of the essential role of peroxiredoxin in protecting cells against H~2~O~2~-induced cell damage and apoptosis, down-regulation in placentae of women with PE emphasizes the role of oxidative stress as an important factor in the development of PE ([@DEU268C13]). Furthermore, recent studies have advocated that oxidative stress stimulates androgen-producing steroidogenic enzymes leading to the hyperandrogenism observed in women with PCOS ([@DEU268C10]).

As the proteins are the functional units within the cellular environment, analysis of proteomes provide what is presently the finest depiction of disease aetiology at a molecular level.

The discovery of biomarkers poses a challenging task and this is mainly due to the different nature of the samples tested (serum, plasma, urine, tissue). All these samples contain proteins in abundance which reflects their biological activity. It is often thought that tissue biopsy may reflect the disease process more accurately; however, the low invasiveness, low cost and easy sample collection and processing makes the use of body fluids a more attractive option in biomarker studies ([@DEU268C54]). The key to overcome the issues with different samples and analysis is vigilance in sample preparation, state of the art mass spectrometry, careful data processing and cautious data analysis.

One important consideration is that in our analysis, we searched for common biomarkers (to PE and PCOS) but identified from proteomic analyses of different tissues. This raises the question as to whether specific changes in protein (biomarker) expression in, for example, placenta, would be accurately reflected in serum or plasma. Certainly, tissues are characterized by a higher protein complexity than blood, but with the latter is more challenging to interrogate in the initial biomarker discovery phase due to the large dynamic range of blood-derived protein concentrations. Indeed, this is an important question for clinical proteomic analyses in general and not one that has been extensively addressed to date in an evidence-based manner. A few studies relevant to different clinical conditions (such as PE and PCOS) have considered correlations between levels of tissue and circulating biomarkers, with differing results. For example, one study of individuals with abdominal aortic aneurysms found no correlation between levels of amino-terminal pro-peptide of type III pro-collagen between plasma and tissue ([@DEU268C47]). In contrast, a recent study of non-small lung cell carcinoma demonstrated that GP88 (pro-granulin) is both a tissue and circulating disease biomarker ([@DEU268C16]), suggesting an association in expression levels. In the context of our own work, it would be of particular interest to perform a future study comparing relative expression levels of proteins in placenta, follicular fluid, ovarian and omental biopsies compared with serum/plasma, and determine whether under conditions where changes in tissue expression occur, such changes are also manifest in the circulation.

The various quantitative and semi-quantitative proteomic techniques used up till now poses a challenge because of the disparate accuracy of the results. We chose to report differential protein expression as either up- or down-regulated which is consistent with previously published systematic reviews of proteomic biomarkers ([@DEU268C4]) as there is a concern that systematic reviews and meta-analysis are influenced by the clinical heterogeneity. The use of inflammatory markers for diagnosing diseases is another challenge as these markers can also be associated with various other concomitant disease processes. This is a limitation that is known to all biomarker studies of complex diseases ([@DEU268C33]). It is not recommended at this stage that the biomarkers identified in our study are used as conclusive biomarkers of PE and PCOS. Our results provide a framework on which future work can be based and validation studies can be used to better understand the pathophysiological mechanisms linking PCOS and PE.

Proteomic and other 'omic' technologies offer a great prospective for creating new insights into disease aetiology, but it is not without limitations. The relatively slow pace at which research findings have been translated into clinical care is of a concern ([@DEU268C55]). Proteomic techniques have a restricted ability to detect low-abundance proteins, some of which may have diagnostic potential. Moreover, there is a risk of false-positive results as the sample sizes are small ([@DEU268C44]). Emphasis should be placed on data assimilation from primary proteomic studies in order to improve interpretation of research findings and prospective endorsement ([@DEU268C23]).

All these issues highlight the fact that there should be more collaboration. This would ensure data synthesis and integration (as in this review) in order to narrow down replicated biomarkers which can be then be validated in subsequent hypothesis-driven research. We see great significance in disseminating our findings to the scientific community as it is vital for the progress in the area of 'omic' research.

Conclusion {#s4a}
----------

Through integrating data from proteomic studies of PE with data from proteomic studies of PCOS, we have for the first time identified a panel of five biomarkers of PE which are common to women with PCOS; these are transferrin, fibrinogen α, β and α chain variants, kininogen-1, annexin 2 and peroxiredoxin 2. If validated, these biomarkers could provide a useful framework on which the knowledge base in this area could be developed. This goal can be achieved by greater collaboration between clinicians, basic scientists and mathematicians.
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[^1]: LC-ESI-MS/MS, liquid chromatography electrospray ionization tandem mass spectrometry; 2D-GE/2DE, 2D (gel) electrophoresis; 2D-LC, 2D liquid chromatography; DIGE, differential gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; iTRAQ, isobaric tags for absolute and relative quantification; LC-MS/MS, liquid chromatography--tandem mass spectrometry; MALDI-TOF, matrix-assisted laser desorption time-of-flight; MS, mass spectrometry; *n*, number of participants; PE, pre-eclampsia; Q TOF, quadrupole time of flight; SD, standard deviation; SELDI-TOF, surface-enhanced laser desorption ionization time-of-flight; SRM, selective reaction monitoring; 2D-LC-MS/MS, multidimensional liquid chromatography tandem mass spectrometry; 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis. IGFALS, insulin-like growth factor binding protein; MCAM, melanoma cell adhesion molecule.

[^2]: ^a^Vitamin D binding protein is found on the lists of over- and under-represented proteins with different protein database accession numbers. When careful analysis of the peptide data was done manually, it was revealed that the majority of peptides were under-represented in the PE plasma, whereas three peptides matching to a different allele (GC2, T420 K) were at a relatively higher abundance in the PE plasma. This observation also shows the potential of this proteomics workflow to detect differences in isoform expression as well as the potential pitfall of interpreting isoform differences as relative abundance changes if the data are not carefully scrutinized ([@DEU268C5].

[^3]: 1, description of selection criteria; 2, the spectrum of patients used in each study is representative of the patients who will receive the test in practice; 3, full description of the sample size; 4, adequate description of the procedure and timing of the collection of biological sample with respect to clinical factors; 5, adequate description of handling and pre-analytical procedures---were these the same for the whole sample?; 6, The period between the reference standard and the index test is short enough to reasonably guarantee that the target condition did not change between the two tests; 7, The reference standard is likely to correctly classify the target condition; 8, the whole sample or a random selection of the sample received verification using a reference standard of diagnosis; 9, the patients received the same reference standard regardless of the result of the index test; 10, the execution of the index test is sufficiently described to its permit replication; 11, the execution of the reference standard is sufficiently described to its permit replication; 12, the index test results are interpreted without knowledge of the results of the reference standard; 13, the reference standard results are interpreted without knowledge of the results of the index test; 14, the same clinical data are available when test results are interpreted as it would be when the test is used in practice; 15, any uninterpretable/intermediate test results are reported; 16, the presence of overfitting was most likely avoided; Y, criterion achieved; N, criterion not achieved or not mentioned; HQ, high quality; LQ, low quality; N/A, not applicable.
